Original Article

When to Consider Invasive Lymph Node Staging in Non–Small-Cell Lung Cancer? A Novel Scoring System Utilising Metabolic Parameters in 18F-FDG PET/CT

Figen Öztürk Ergür[a], Ayperi Öztürk[a,*], Özlem Özdağ[a], Ebru Tatcı[b], Özlem Özmen[b], Aydın Yılmaz[a]

[a] Health Sciences University, Atatürk Sanatoryum Education and Research Hospital, Interventional Pulmonology, Ankara Turkey
[b] Health Sciences University, Etlik City Hospital, Nuclear Medicine, Ankara Turkey

ABSTRACT

Objective: The maximum standardised uptake value (SUVmax) is a widely utilised metric in positron emission tomography/computed tomography for clinically staging non–small-cell lung cancer (NSCLC), yet the reliability of SUVmax remains controversial. We herein aimed to assess the effectiveness of semi-quantitative parameters, encompassing size, SUVmax, metabolic tumour volume (MTV), total lesion glycolysis (TLG) and heterogeneity factor (HF), in evaluating both primary tumours and lymph nodes (LNs) on positron emission tomography/computed tomography. A novel scoring system was devised to appraise the role of semi-quantitative parameters and visually evaluate LNs for nodal staging.
Materials and Methods: Patients with pathological NSCLC, diagnosed between 2014 and 2019 and clinically staged I-III, were enrolled in the study. Patient demographics, including age, sex, tumour location, diameter, tumour-node-metastasis stage, as well as SUVmax, MTV, TLG and HF parameters of primary tumours and LNs, were documented.
Results: The analysis comprised 319 patients and 963 LNs. Patients had a mean age of 61.62 years, with 91.5% being male. Adenocarcinoma exhibited a histological association with LN metastasis (P = 0.043). The study findings revealed that tumour size, SUVmax, MTV, TLG and HF did not significantly affect the detection of LN metastasis. Conversely, non-squamous cell carcinoma, LNs exhibiting higher FDG levels than the liver, LN size, SUVmax, MTV and TLG were identified as risk factors (P < 0.0001). The identified cut-off values were 1.05 cm for LN size, 4.055 for SUVmax, 1.805 cm^3 for MTV and 5.485 for TLG. The scoring system incorporated these parameters, and visual assessment indicated that a score of ≥3 increased the risk of metastasis by 14.33 times.
Conclusion: We devised a novel scoring system and demonstrated that LNs with a score of ≥3 in patients with NSCLC have a high likelihood of metastasis. This innovative scoring system can serve as a valuable tool to mitigate excessive and extreme measures in the assessment of invasive pathological staging.

Introduction

Non–small-cell lung cancer (NSCLC) accounts for approximately 85% of all lung cancers, with up to 40% of patients with NSCLC exhibiting metastatic disease upon diagnosis.[1] Accurate mediastinal staging is imperative for devising optimal treatment strategies and effectively managing patients. While invasive procedures serve as the gold standard for nodal staging, their utilisation is hampered by inherent risks of complications, cost concerns and diagnostic delays.[2] Non-invasive mediastinal lymph node (LN) staging presents a promising alternative to identify patients requiring invasive interventions. Positron emission tomography/computed tomography (PET/CT) with 18F-fluorodeoxyglucose (18F-FDG) emerges as a non-invasive modality for cancer staging, restaging, radiotherapy planning and treatment response prediction.[3,4]

However, reliance solely on the maximum standardised uptake value (SUVmax) for quantifying metabolic activity in 18F-FDG PET/CT poses limitations. SUVmax provides a single voxel value that is insufficient for capturing the entirety of tumour volume or offering comprehensive insights into overall tumour metabolism. Consequently, it falls short as a determinant of the heterogeneous nature of lung tumours characterised by distinct biological

* Corresponding author.
E-mail address: drayperi@gmail.com (A. Öztürk).

activity regions.[5] Moreover, guidelines caution against considering SUVmax of the primary tumour as a reliable biomarker for determining disease prognosis.[6,7] Recent research underscores the potential of alternative parameters such as metabolic tumour volume (MTV), total lesion glycolysis (TLG) and heterogeneity factor (HF), derived from SUV calculations on PET/CT scans, as robust prognostic indicators.[5,8–12] MTV reflects metabolically active tumour volume, while TLG signifies both volumetric and metabolic tumour burden, offering more nuanced measures of tumour aggressiveness and burden.[13–16] Notably, intra-tumoural heterogeneity, quantified by the FDG uptake heterogeneity factor, emerges as a salient predictor of lymph node metastasis (LNM) across various malignancies.[17–19] Leveraging semi-quantitative parameters of the primary tumour and LNs in F-18 FDG PET/CT, our study aims to discern their efficacy in predicting LNM during NSCLC clinical staging. Additionally, we analyse the utility of a novel scoring system incorporating these parameters alongside visual LN assessment for enhanced mediastinal staging accuracy.

Methods

Patient selection

This retrospective analysis encompassed 319 patients and 963 LNs diagnosed with early and locally advanced NSCLC at the Atatürk Sanatorium Training and Research Hospital of the University of Health Sciences, Ankara, between January 2014 and December 2019. The hospital's computer system archives PET/CT scan images obtained before treatment, primary pathological lung cancer diagnoses, mediastinal LN pathological diagnoses obtained via endobronchial ultrasound (EBUS) and/or surgical methods (mediastinoscopy or operation) and clinical follow-up data. These data were retrieved from the system and file records. Patients with complete information available were included in the study. F-18 FDG PET/CT scans of patients with NSCLC retrievable from our hospital database were re-examined. Patients staged as I, II (early clinical stages) and III (locally advanced stage) according to the 8th tumour node metastasis staging system were included in the study.

The following patients were excluded: 1. Patients with indistinguishable primary tumour and LN involvement on PET/CT due to proximity and those receiving malignancy treatment between PET/CT and LN sampling; 2. Patients undergoing any malignancy treatment between PET/CT and LN sampling; 3. Stage III patients with scalene/supraclavicular LN metastases; 4. Patients with distant disease (stage 4) and, 5. Patients with unavailable results in the hospital database.

The research commenced upon obtaining approval from the Ethics Committee of the University of Health Sciences, Keçiören Training and Research Hospital, in accordance with guidelines (14.09.2021/2012-KAEK-15/2365).

LN sampling

Given the retrospective nature of the study, patients undergoing EBUS and/or surgical LN sampling were included. As per the European Society of Thoracic Surgeons[20] and European Society for Medical Oncology[21] guidelines, the diagnostic approach to NSCLC-suspected lesions is guided by clinical stage:

Mediastinal pathological staging is recommended for central tumours, suspected N1 disease and tumours >3 cm. Additionally, younger age, adenocarcinoma (ADC) histology and higher N stage on PET/CT, N2 and N3 are deemed risk factors for the disease. For lesions suspicious of T1a-cN0M0 (stage I) with a peripheral location of <3 cm or clinically mediastinal location and no suspicion of distant metastasis with hilar LN involvement, surgery is advised.[20,21]

A comparative investigation into the optimal number of LN stations necessitating sampling through the combined utilisation of endoscopic ultrasound (EUS) and EBUS for mediastinal staging remains unexplored. Nonetheless, established protocols related to mediastinoscopy, regarded as the gold standard for mediastinal staging, provide valuable insights. According to the 2014 guideline on mediastinal staging by the European Society of Thoracic Surgeons, the evaluation and sampling of at least stations 4L, 4R and 7 are recommended during cervical mediastinoscopy. Additionally, the guideline suggests the sampling of LNs 2R and 2L, if present, and LNs 5 and 6, which could potentially influence treatment strategies, particularly in cases of left-sided tumours. In the guide outlining the combined application of EBUS and EUS, it is advised to sample at least stations 4R, 4L and 7 for comprehensive mediastinal staging (EBUS + EUS). Moreover, the guidelines recommend sampling pathological LNs with PET/CT.[20,21]

Data collection

Demographic data, including age and sex, alongside pathological diagnoses of the primary tumour and LNs, were retrospectively analysed. Patients were stratified into subgroups of ADC, squamous cell carcinoma (SCC), adenosquamous cell carcinoma and not otherwise specified based on a review of pathological diagnoses of the primary tumour. The 8th tumour node metastasis staging system was applied for classification.[22]

FDG-PET/CT scan protocol

Patients underwent FDG PET/CT imaging using a Siemens Biograph-6-HI-REZ integrated PET/CT scanner (Siemens Medical Solutions, Knoxville, Tennessee, USA). The imaging protocol entailed a 6-h fasting period before scanning, with patients encouraged to drink water. Following confirmation of acceptable peripheral blood glucose levels (<180 mg/dL), patients received an intravenous injection of 370–555 MBq (10–15 mCi) FDG and underwent a 60-min rest before scanning. Initially, CT scans were conducted from the head to the thigh with the arms elevated, utilising the CareDose (Siemens) protocol. Subsequently, PET data acquisition entailed 3-minute scans per bed position, spanning 6–8 bed positions. CT data were utilised for attenuation correction, and PET images were reconstructed employing a Gaussian post-filtering algorithm with 4 iterations and 8 subsets.

2.5 F-18 FDG PET/CT image evaluation

All PET/CT scans of the enrolled patients were analysed by a certified nuclear medicine specialist. After image reconstruction, the SUVmax and SUVmean values were calculated by outlining the region of interest around the primary tumour in the PET/CT images (fig. 1). The size and location of the primary tumour, including right/left and central/peripheral, were documented (Fig. 1a). SUVmax was determined as the maximum SUV value of the region of interest using the following formula: tissue concentration (MBq/mL)/injected FDG activity (MBq)/body weight (g). MTV was defined as the volume of the tumour exceeding the SUV threshold of 2.5, while TLG was calculated by multiplying SUVmean and MTV. LNs exhibiting higher FDG uptake than the mediastinal blood pool was categorised as positive. In cases of multiple positive LNs within the same station, the study included the SUVmax value of the LN with the highest FDG uptake. The MTV of the LNs was calculated using a 2.5 SUV threshold value. In cases of multiple LNs within the same station, the MTV of all LNs was summed, and TLG was calculated by averaging the SUVmean values for the LNs within that station. Furthermore, subcategories were established through

Fig. 1. **1a.** An example of measurement of primary tumor and lymph node metabolic parameters in 18F-FDG PET/CT imaging. Figure represents primary tumor and metastatic lymph node. Primary tumor SUVmax 15.63 and MTV 179.66 cm^3; lymph node SUVmax 8.67 and MTV 6.94 cm^3. **1b.** An example of the heterogeneity factor calculations. The graph in the figure shows that HF is calculated by taking the derivative of the volume threshold function for each tumor. The absolute value of the calculated slope forms the HF value.

Table 1
Characteristics of patients.

	N	%
Age	61.2 ± 8.23	25–82 (min–max)
Sex		
Male	292	91.5
Female	27	8.5
Diagnostic methods		
FOB	108	33.86
TTNAB	127	39.81
EBUS	78	24.45
Surgery	6	1.88
Histologic subtypes		
ADC	114	35.74
SCC	166	52.04
ADSC	7	2.19
NOS	32	10.03

FOB: fiberoptic bronchoscopy; TTNAB: transthoracic fine needle aspiration biopsy; EBUS: endobronchial ultrasonography; ADC: adenocarcinoma; SCC: squamous cell carcinoma; ADSC: adenosquamous carcinoma; NOS: not otherwise specified; Min: minimum; Max: maximum.

visual comparison of the FDG uptake in the LN against that in the mediastinum and liver.

The MTV values were computed for primary tumours and LNs using SUVmax threshold values of 40%, 50%, 60%, 70% and 80%. To determine HF, the volume-threshold function derivative of the MTV values obtained from each tumour threshold value was calculated using linear regression (Fig. 1b). HF values below 40% and above 80% were excluded from the analysis, as prior studies indicated that values below 40% indicate excessive normal tissue background activity, and those above 80% are susceptible to small volume and partial volume effects.[18,19,23] All calculations were performed using the Siemens automatic operating system.

Development of a scoring system

We identified statistically significant cut-off values for LN metabolic parameters potentially linked to LN metastasis. LNs meeting or exceeding the cut-off values for size, SUVmax, MTV and TLG, and exhibiting higher FDG uptake than the liver on visual comparison, were assigned with a score of 1. Nodes below the cut-off points or with lower FDG uptake than the liver were assigned with a score of 0 (Table 3). A 5-point scoring system was established, and the statistical robustness of this system was evaluated.

Statistical analysis

Statistical analyses were conducted using IBM SPSS 25.0 (IBM Corp., Armonk, NY, USA). Descriptive statistics were applied: continuous and discrete numerical variables were expressed as mean ± standard deviation, while categorical variables were presented as counts and percentages. The Mann–Whitney U test was used for group comparisons, the chi-square method for analysing relationships between categorical data, and the Spearman correlation test for assessing variable relationships. Variables demonstrating statistical significance (P < 0.05) in predicting LNM in univariate analysis were included in a multivariate logistic regression model. The diagnostic performance of independent risk factors (LN size, SUVmax, MTV and TLG) identified for predicting LNM in the multivariate analysis was evaluated through receiver operating characteristic (ROC) curve analysis. Threshold values were determined using the Youden index, and a scoring system was developed by ranking variables with independent risk factors. The scoring system's performance was assessed via ROC analysis, and diagnostic accuracy rates were calculated. A significance level of p < 0.05 was used.

Results

Patient characteristics

From January 2014 to December 2019, 2,240 patients with NSCLC underwent screening. Of these, 963 LNs from 319 patients meeting the inclusion criteria were included in this study (fig. 2). The median age of the cohort was 61.2 ± 8.23 years (range: 25–82) years, with males accounting for 91.5% (n = 292) (table 1). SCC was the most common primary histology, present in 52.04% of cases, followed by ADC at 35.74% (n = 114). Among the 319 patients, 16.6% (n = 53) were classified as stage I, 26.6% (n = 85) as stage II and 56.7% (n = 181) as stage III. The mean tumour size was 5.05 ± 2.27 cm, with the majority located centrally (67.7%, n = 216) and on the right side (58.6%, n = 187).

Tumor size was measured in centimeters and categorized as T1, T2, T3, or T4, by the tumor, node, and metastasis (TNM) staging system. The T factor was taken from operated patients, whereas PET/CT measurements were taken from unoperated patients. The results showed that 21.6% (n = 69) of patients were T1, 31.3% (n = 100) were T2, 27.9% (n = 89) were T3, and 19.1% (n = 61) were T4. The number of patients with pN0 staging was 145 (45.4%), while the number of cN0 patients was 19 (5.96%). Of the patients, 109 (34.2%)

Fig. 2. Flow chart of the study.

Table 2
Results of univariate and multivariate logistic regression analyses in predicting LN metastasis.

Variables	Univariate OR (95% CI)	Univariate p-value	Multivariate OR (95% CI)	Multivariate p-value
LN > MBPS	15.460 (10.126–23.603)	0.001	–	0.434
LN > L	17.001 (8.584–33.670)	0.001	1.933 (1.029–3.630)	0.048
SUVmax	17.828 (12.071–26.331)	0.001	3.108 (1.584–6.096)	0.001
MTV	1.341 (1.275–1.410)	0.001	1.067 (0.293–3.891)	0.014
TLG	1.074 (1.060–1.087)	0.001	1.080 (1.037–1.123)	0.001
Size	12.951 (8.558–19.599)	0.001	1.281 (0.689–2.383)	0.005
Non-SCC histology	0.497 (0.363–0.681)	0.001	5.113 (2.527–10.345)	0.001
ADC	1.483 (1.241–1.971)	0.041	–	0.086

SUVmax: maximum standardised uptake value; MTV: metabolic tumour volume; TLG: total lesion glycolysis; LN: lymph node; L: liver; MBPS: mediastinal blood pool activity; SCC: squamous cell carcinoma; ADC: adenocarcinoma; OR: odds ratio; CI: confidence interval.

were pN2 staged, while 119 (37.3%) were cN2 staged. The concordance between clinical and pathological N factors and stages was poor ($\kappa = 0.155$, $p < 0.0001$; $\kappa = 0.198$, $p < 0.0001$, respectively). A significant difference was observed in N factor and pathological staging according to cancer subtypes ($p = 0.002$; $p = 0.01$, respectively). Among SCC patients, 54.8% (n = 91) were N0, while 43% (n = 49) of ADC patients exhibited N2 disease. ADC accounted for 44.4% (n = 12) of pN3 lymph nodes. A total of 64.9% (n = 74) of ADC patients were diagnosed at stage III. Most patients diagnosed at an early stage (stages I-II) were diagnosed with SCC (p = 0.01). Of the central tumours, 61.6% (n = 133) were diagnosed as SCC, while 50.5% of peripheral tumours were diagnosed as ADC. In contrast to ADC, where the distribution of central and peripheral tumours was comparable, a significantly higher proportion of SCC cases (80.1%) were observed in the central region (p = 0.0001).

PET/CT characteristics of primary tumour and LNs

In our study, the PET/CT findings for primary tumours were as follows: mean SUVmax 15.79 ± 15.21, MTV 86.56 ± 100.03, TLG 612.78 ± 754.09 and HF 0.84 ± 0.95. Although no statistically significant difference was observed, SUVmax, MTV, TLG and HF measurements showed higher values in tumours without LNM than in those with LNM (P > 0.05). No correlation was found between tumour SUVmax and pathological staging (P = 0.09); however, significant positive correlations were observed between tumour

size (P < 0.001, r = 0.449), MTV (P < 0.001, r = 0.415), TLG (P < 0.001, r = 0.380), HF (P < 0.001, r = 0.432) and pathological staging.

The average time between PET/CT imaging and lymph node sampling was 18.02 ± 15.72 days. A total of 963 LNs were analysed in our study, of which 209 (21.7%, n = 209) showed metastasis. The LNs had a mean size of 1.01 ± 0.52 cm, SUVmax of 4.49 ± 3.62, MTV of 3.64 ± 8.62 and TLG of 17.07 ± 50.95. Our results demonstrated a positive correlation between the size of the LNs and SUVmax, MTV and TLG (r = 0.635, r = 0.657, r = 0.662, P < 0.0001, respectively). Comparison between metastatic and non-metastatic LNs with LN size, SUVmax, MTV and TLG values showed that the measured metabolic parameters were significantly higher in patients with LNM than in those without LNM (P = 0.0001). A visual comparison of 958 LNs with FDG uptake and liver and mediastinal blood pool activity (MBPS) showed that LNs with visually high FDG uptake from MBPS and liver had significantly more metastases (P < 0.001). The sensitivity, specificity, negative and positive predictive values of PET-CT in detecting lymph node metastasis were 95.7%, 43.5%, 97.3%, and 31.9%, respectively.

Univariate and multivariate regression analyses results in predicting LN metastasis

Multivariate logistic regression analysis was used to assess the variables associated with LNM in univariate analyses. Our results suggest that LNs with higher uptake than MBPS and ADC histol-

Table 3
Cut-off values and diagnostic accuracy of LN size, SUVmax, MTV and TLG measurements in predicting LN metastasis.

	Area	p	95% CI		Cut-off	Sens.%	PPV %	Spec. %	NPV %	OR
			Lower	Upper						
Size	0.795	0.0001	0.759	0.831	1.05	65.10	48.06	80.50	89.30	7.69
SUVmax	0.879	0.0001	0.848	0.909	4.055	80.90	53.8	80.80	93.84	17.75
MTV	0.849	0.0001	0.817	0.882	1.805	77.50	48.80	77.50	92.55	11.84
TLG	0.860	0.0001	0.828	0.892	5.485	78.0	49.54	78.0	92.74	12.76

SUVmax: maximum standardised uptake value; MTV: metabolic tumour volume; TLG: total lesion glycolysis; Sens: sensitivity; Spec: specificity; PPV: positive predictive value; NPV: negative predictive value; OR: odds ratio; CI: confidence interval.

Table 4
Distribution of data included in the scoring system.

		pN+ N (%)	pN− N (%)	Total N (%)	Point
LN size (cm)	>1.05	136 (14.19)	145 (15.14)	281	1
	≤1.05	72 (7.52)	605 (63.15)	677	0
LN SUVmax	>4.055	168 (17.54)	143 (14.92)	311	1
	≤4.055	40 (4.18)	607 (63.36)	647	0
LN MTV (cm³)	>1.805	162 (16.91)	168 (17.54)	330	1
	≤1.805	46 (4.80)	582 (60.75)	628	0
LN TLG	>5.485	163 (17.01)	164 (17.12)	327	1
	≤5.485	45 (4.70)	586 (61.17)	631	0
LN > L		179 (18.68)	214 (22.34)	393	1
LN ≤ L		29 (3.03)	536 (55.95)	565	0
Score					Total score: 5
0 point		22 (10.58)	444 (59.2)	466 (48.64)	
1 point		12 (5.77)	100 (13.33)	112 (11.69)	
2 point		12 (5.77)	58 (7.73)	70 (7.31)	
3 point		4 (1.92)	32 (4.27)	36 (3.75)	
4 point		30 (14.42)	58 (7.73)	88 (9.19)	
5 point		128 (61.54)	58 (7.73)	186 (19.42)	
0–2 points		46 (22.12)	602 (80.3)	648 (67.64)	
3–5 points		162 (77.88)	148 (19.7)	310 (32.36)	

SUVmax: maximum standardised uptake value; MTV: metabolic tumour volume; TLG: total lesion glycolysis; L: liver; LN: lymph node.

ogy are not risk factors for LNM (P = 0.434; P = 0.086, respectively). Conversely, LN size, SUVmax, TLG, MTV, high liver FDG uptake and non-SCC histology are independent risk factors for predicting LNM. The results of univariate and multivariate regression analyses for predicting LN metastasis are shown in Table 2.

Cut-off values of LN size, SUVmax, MTV and TLG measurements and scoring system

ROC analysis curves for the prediction of LN metastasis are presented in Fig. 2a. The area under the curve (AUC) values were 0.795, 0.879, 0.849 and 0.860 for LN size, SUVmax, MTV and TLG, respectively (Table 3). Among the PET parameters, LN SUVmax exhibited the best predictive performance for LNM, with an optimal cut-off value of 4.055 (sensitivity 80.9%, specificity 80.8%).

Values above the defined threshold for LN size, SUVmax, MTV and TLG, as well as those with LN FDG uptake greater than that of the liver, were scored 1. Values below the threshold and LN FDG uptake less than that of the liver were scored 0. We developed a 5-point scoring system (table 4). A total of 958 LNs were scored, with 466 receiving a score of 0 and 186 receiving a score of 5. LNM was detected in 68.82% (n = 128) of nodes graded with a score of 5. In comparison, 10.58% of metastatic nodes were scored 0 and 61.54% received a score of 5. Using ROC analysis, a cut-off value of 2.5 points was ascertained for these nodes (Fig. 3b). A score greater than 2.5 was associated with a 14.33-fold increased risk of LNM. Table 5 shows the sensitivity, specificity, positive and negative predictive values and odds ratios.

Discussion

This study delved into the efficacy of various semi-quantitative parameters, such as LN size, SUVmax, MTV and TLG, in predicting mediastinal LN metastasis. Additionally, we explored how these parameters, combined with primary tumour characteristics, including size, SUVmax, MTV, TLG, and HF, measured via 18F-FDG PET/CT, contribute to predictive accuracy. Our research suggests that a scoring system that integrates lymph node size, SUVmax, MTV, TLG and visual comparison is more effective in non-invasively staging lymph nodes for detecting positivity than relying on these parameters individually. Additionally, our study boasts the largest sample size to date for evaluating lymph node parameters.

Approximately 60%–70% of lung cancer diagnoses occur in individuals aged 65 or older, with men exhibiting a higher incidence. Notably, Lu et al. comprehensive analysis spanning 1973 to 2015 revealed a declining incidence of lung cancer in men, decreasing with a rising trend in women. Furthermore, their study highlighted a higher 5-year survival rate among women. Consistent with prevailing trends, our study predominantly comprised male participants (91.5%, n = 292), with an average age at diagnosis of 61.62 ± 8.23 years.

Age and tumour size serve as well-established risk factors for LNM in NSCLC.[24] For instance, investigation of Kong et al. on patients with resected adenocarcinoma *in situ* (adenosquamous cell carcinoma) revealed a heightened likelihood of LNM among individuals younger than 65 years with tumours larger than 3 cm in size.[25] Intriguingly, neither sex nor histological subtype

Fig. 3. **3a.** ROC analysis curves of lymph node size, SUVmax, MTV, and TLG measurements. **3b.** ROC analysis curve of the scoring system.

Table 5
Analysis of the scoring system for predicting LN metastasis.

			Presence of LNM							
		p	95% CI							
	Area		Lower	Upper	Cut-Off	Sens	PPV	Spec	NPV	OR
Score	0.848	0.0001	0.816	0.880	2.5	77.9%	52.23%	80.3%	92.9%	14.33

PPV: positive predictive value; NPV: negative predictive value; OR: odds ratio; Sens: sensitivity; Spec: specificity; CI: confidence interval; LN: lymph node; LNM: lymph node metastasis.

significantly influenced LNM likelihood, with optimal cut-off points identified at 64.5 years and 2.85 cm for age and tumour size, respectively (AUC: 0.567, 95% CI: 0.544-0.591; AUC: 0.677, 95% CI: 0.656-0.698, respectively). Similarly, in a study focusing on peripheral early-stage lung ADC, tumour size emerged as a robust predictor of LNM, while age and sex exhibited negligible impact.[26] However, our study did not unveil any significant associations between age, sex, tumour size and LNM (P = 0.4, P = 0.607, P = 0.62). Notably, Miao et al. reported analogous findings, underscoring the non-predictive nature of age, sex and tumour size in patients operated for lung ADC.[27] It is crucial to acknowledge the inherent heterogeneity within NSCLC subtypes, which may contribute to divergent prognostic outcomes across studies. The discrepancies observed in study outcomes may be attributed to heterogeneity.

LNM stands out as a key marker of malignancy, often indicating highly invasive tumours with poor prognoses.[28] While invasive methods are typically preferred for mediastinal LN staging, there are situations, such as in patients with significant comorbidities, where invasive procedures may not be viable. In such cases, treatment decisions can be guided by a PET/CT-based clinical staging approach.[29,30] In our study, the development of a scoring system based on predefined PET/CT parameters revealed a substantial 14-fold increase in the risk of metastasis in LNs scoring 3 and above.

Despite its widespread use, SUVmax, as a single parameter, has been found to be an unreliable indicator and inadequate for predicting prognosis, as highlighted in several studies.[6,7,31,32] Relying solely on SUVmax for PET/CT interpretation can lead to the overlooking of LNM, with reported incidence rates varying between 8% and 58%.[33] In another study, the false positive rate of PET-CT was found to be 25% (57 of 234 patients). Upon further

analysis, the researchers determined that the histological subtype (squamous cell carcinoma) was the primary reason for this discrepancy.[34] Recognising these limitations, recent research has focused on alternative methods for predicting metastasis. Volumetric parameters such as MTV, TLG and HF in PET/CT imaging have emerged as promising predictors and prognostic markers for LNM and staging across various cancer types. Clear and concise imaging metrics could significantly enhance cancer diagnosis and management.[8,11,12,14,15,18,35] Our study revealed no association between the semi-quantitative parameters of the primary tumour and LNM. Although increased values for tumour size, MTV, TLG and HF were linked to advanced stage, they did not correlate with primary tumour SUVmax. These findings underscore the limited reliability of SUVmax as a parameter. However, they do suggest the potential suitability of other parameters as prognostic indicators, a notion supported by the study of Ouyang et al.[17] In their analysis, tumour SUVmax and SUVmean values for ADC and SCC were not significant factors for LNM. Nevertheless, primary tumour MTV emerged as a crucial predictive factor, with an optimal cut-off value of 29.50 (AUC: 0.659, sensitivity: 70.4%, specificity: 59.2%) for occult LNM in patients with stage I ADC (P = 0.044; OR: 1.671, 95% CI: 1.013-2.756). Similarly, an optimal cut-off value of 0.198 (AUC: 0.759, sensitivity: 88.9%, specificity: 61.1%) for primary tumour HF in patients with SCC was identified as an independent risk factor (P = 0.023; OR: 8.799, 95% CI: 1.351–57.317).

In the mediastinal region, LNs with a short axis diameter greater than 10 mm are commonly diagnosed as malignant on contrast-enhanced CT[36]; however, their sensitivity is relatively low at 59%, with a specificity of 78%.[37] On the other hand, PET/CT imaging demonstrates a higher sensitivity (85%) in LNs larger than 1 cm in

diameter, dropping to 32% in smaller nodes.[38] Kuzucuoglu et al. found that LNs with high FDG uptake, a size greater than 16 mm and an SUVmax greater than 2.9 have a higher risk of metastasis.[39] However, assessing LN metabolic and volumetric parameters for metastasis prediction is relatively uncommon compared with tumour evaluations. In a separate study, the SUVmax values of metastatic LNs were notably higher than in non-metastatic ones when considering SUVmax of ≥ 4 as PET-positive for metastasis.[40] In this study, a correlation was found between tumour SUVmax, histological subtype and tumour size, with no such correlation found for LN SUVmax. Studies have established an SUVmax threshold of ≥ 2.5 as appropriate for detecting pathological LNs.[41] A meta-analysis suggested that for the mediastinal staging of NSCLC, PET/CT based on the SUVmax ≥ 2.5 positivity criterion has a sensitivity of 81% and specificity of 79.4%, while based on LN FDG uptake higher than the background activity criterion, the sensitivity and specificity estimates were 77% and 90%, respectively.[4]

In a 2016 study, Rogasch et al. demonstrated that LNs with visual FDG uptake higher than that of the liver (LN > L) were 3.3 times more effective in detecting malignancy than LN with lower uptake than the liver but with more MBPS (LN > MBP).[42] This study involved 86 patients with NSCLC, with three experts of varying experience levels analysing the PET images. Their evaluations produced comparable results, indicating the reproducibility of the suggested classification. In a related recent study with a larger patient sample, it was noted that LNs with higher uptake from the liver (LN > LBC) necessitate less invasive staging than those with higher MBPS (LN > MBPS).[43] However, while a lower false-positive rate would be achieved, there is a risk of missing more N2 diseases, including multiple diseases. Therefore, to mitigate excessive invasiveness in staging, the authors proposed limiting invasive staging to patients with all three risk factors (cN1, tumours larger than 3 cm and central tumours), in line with existing guideline recommendations.[20,21]

In our study, we observed a 1,933-fold visual increase in the risk of LNM with high FDG uptake from the liver. Our results showed that 44.3% (n = 424) of LNs were oversampled because high FDG uptake corresponding to the mediastinal blood pool (LN > MBPS) was considered positive for PET. If LNs with a higher FDG uptake than the liver (LN > L) had been considered positive, this figure would have been 22.3%. Notably, our scoring system achieved the lowest number of unnecessary invasive procedures, with a rate of 15.1%.

There is a noticeable gap in the current literature regarding LN metabolic parameters, leading to uncertainty about their clinical utility. While LN SUVmax, MTV and TLG have been linked to recurrence,[44] volumetric parameters (MTV and TLG) have been reported to carry a higher prognostic risk than metabolic parameters (SUVmax and SUVmean). A recent study by Nakanishi et al. explored LN SUVmax, MTV, TLG and LPR (LN/primary tumour SUVmax) in 84 pN+ patients, revealing significantly higher values in metastatic LNs than in benign ones.[45] The authors established cut-off values for LN SUVmax and TLG as 4.15 (sensitivity: 79.4%, specificity: 76.2%) and 1.26 (sensitivity: 81%, specificity: 76.2%), respectively. However, MTV, TLG and SUVmax did not emerge as independent risk factors for predicting metastasis. To the best of our knowledge, this investigation was the primary one to examine metabolic parameters in the LN, wherein the authors used an SUVmax cut-off value of 3.5 for calculating MTV and TLG, highlighting potential limitations due to sample size inadequacy.

In a study by Hua et al., which analysed 206 LNs, parameters such as LN size, SUVmax, SUVmean and TLG were found to be higher in metastatic LNs than in non-metastatic ones (P < 0.001). However, MTV was higher in non-metastatic LNs, although not statistically significant.[46] The study identified optimal diagnostic cut-off values as 5.47 for SUVmax, 10.30 for TLG and 9.90 mm for LN size.

Both studies suggest that LN TLG is elevated in metastatic LNs, but differences in results between studies underscore the lack of standardisation in calculating MTV. In our investigation, TLG emerged as a distinct risk factor for LN metastasis, particularly when the SUV cut-off was set at 2.5. If semi-quantitative parameters continue to offer reliable predictions of LN metastasis, the development of an automated system utilising a validated method could enhance clinicians' ability to assess metastatic potential based on routine PET values.

In our study, we identified semi-quantitative measures of LNs and non-squamous histology as independent risk factors for LNM. Our novel scoring system represents a simple and promising approach for treatment planning and monitoring in patients with early and locally advanced NSCLC who are ineligible for invasive staging due to contraindications, refuse surgery, or when traditional methods fail to provide a definitive diagnosis.

It is important to note that this scoring system not only aids in avoiding unnecessary invasive procedures but also ensures prompt initiation of treatment, thus potentially reducing the economic burden on healthcare systems by avoiding unnecessary resource utilisation. Additionally, reducing the time between diagnosis and treatment of lung cancer can lead to better patient outcomes. Overall, we believe that implementing this scoring system could significantly reduce the cost of managing lung cancer while improving patient care.

Limitations

Nonetheless, our study has several limitations. First, its single-centre design constrained the sample size. Second, the retrospective nature of the study meant that not all LNs with heightened uptake on PET/CT were sampled. Moreover, the inclusion criteria focused solely on patients undergoing EBUS for staging, potentially overlooking other cases. Furthermore, LNs evaluated with EBUS exhibiting sonographically benign criteria were not histopathologically evaluated, potentially introducing bias. A prospective study design, especially categorising cancer subtypes separately, could yield more robust results. Additionally, the lack of standardisation in the 18F-FDG PET/CT imaging protocol for measuring MTV and TLG poses a challenge. The segmentation method for determining MTV is still evolving, and there is currently no validated technique. Variability in studies arises from calculations using different SUV threshold values. Moreover, the fixed threshold SUV of 2.5 used to calculate MTV and TLG may lead to overestimation in tumours with high FDG uptake and underestimation in those with low uptake due to the exclusion of areas below the threshold value.

Conclusion

The developed scoring system aims to predict the likelihood of LNM in malignancies and to reduce unnecessary invasive staging. Our research identifies high FDG uptake in LNs from the liver, along with LN size, SUVmax, MTV and TLG, as independent risk factors for LNM. These parameters offer supplementary advantages to current clinical staging methods, potentially decreasing the need for invasive procedures. For individuals with a total score below 2.5, invasive staging may not be warranted. LNs scoring 3 or above exhibit a high likelihood of metastasis, indicating their suitability for invasive pathological staging. However, multi-centre studies with larger patient cohorts are necessary to validate this scoring system before routine implementation. Furthermore, this scoring system could be applied not only for LNM but also for the differential diagnosis of various LN conditions, such as granulomatous, reactive, or anthracotic LNs. Future studies on a larger scale are imperative to comprehensively validate this approach.

Declaration of Congress Abstract

This study has not been published or presented any where before.

Ethic

In this study, national and international ethical rules are observed.

Ethic Board

Ethics Committee of the University of Health Sciences, Keçiören Training and Research Hospital (14.09.2021/2012-KAEK-15/2365).

Financial Disclosure

The authors declared that this study has received no financial support.

Authors' Contributions

Ayperi Öztürk and Özlem Özmen: conceptualization, methodology, software. Özlem Özdağ: data curation, writing- original draft preparation. Ebru Tatcı and Figen Öztürk Ergür: visualization, investigation. Özlem Özmen: supervision, validation. Figen Öztürk Ergür: writing. Aydın Yılmaz and Ayperi Öztürk: reviewing and editing.

Conflict of Interest

No conflict of interest was declared by the authors.

References

1. Molina JR, Yang P, Cassivi SD, Schild SE, Adjei AA. Non-small cell lung cancer: Epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc. 2008;83:584–94.
2. Jalil BA, Yasufuku K, Khan AM. Uses, Limitations, and Complications of Endobronchial Ultrasound. Proc (Bayl Univ Med Cent). 2015;28:325–30.
3. Oriuchi N, Higuchi T, Ishikita T, Miyakubo M, Hanaoka H, Iida Y, et al. Present role and future prospects of positron emission tomography in clinical oncology. Cancer Sci. 2006;97:1291–7.
4. Schmidt-Hansen M, Baldwin DR, Hasler E, Zamora J, Abraira V, Roqué I Figuls M. PET-CT for assessing mediastinal lymph node involvement in patients with suspected resectable non-small cell lung cancer. Cochrane Database Syst Rev. 2014;2014:CD009519.
5. Lim R, Eaton A, Lee NY, Setton J, Ohri N, Rao S, et al. 18F-FDG PET/CT metabolic tumor volume and total lesion glycolysis predict outcome in oropharyngeal squamous cell carcinoma. J Nucl Med. 2012;53:1506–13.
6. Cazaentre T, Morschhauser F, Vermandel M, Betrouni N, Prangère T, Steinling M, et al. Pre-therapy 18 F-FDG PET quantitative parameters help in predicting the response to radioimmunotherapy in non-Hodgkin lymphoma. Eur J Nucl Med Mol Imaging. 2010;37:494–504.
7. Satoh Y, Onishi H, Nambu A, Araki T. Volume-based parameters measured by using FDG PET/CT in patients with stage I NSCLC treated with stereotactic body radiation therapy: prognosticvalue. Radiology. 2014;270:275–81.
8. Chung HH, Kim JW, Han KH, Eo JS, Kang KW, Park NH, et al. Prognostic value of metabolic tumor volume measured by FDG-PET/CT in patients with cervical cancer. Gynecol Oncol. 2011;120:270–4.
9. Hyun SH, Ahn HK, Kim H, Ahn MJ, Park K, Ahn YC, et al. Volume-based assessment by (18)F-FDG PET/CT predicts survival in patients with stage III non-small-cell lung cancer. Eur J Nucl Med Mol Imaging. 2014;41:50–8.
10. Chung HW, Lee KY, Kim HJ, Kim WS, So Y. FDG PET/CT metabolic tumor volume and total lesion glycolysis predict prognosis in patients with advanced lung adenocarcinoma. J Cancer Res Clin Oncol. 2014;140:89–98.
11. Son SH, Kim DH, Hong CM, Kim CY, Jeong SY, Lee SW, et al. Prognostic implication of intratumoral metabolic heterogeneity in invasive ductal carcinoma of the breast. BMC Cancer. 2014;14:585.
12. Kwon SH, Yoon JK, An YS, Shin YS, Kim CH, Lee DH, et al. Prognostic significance of the intratumoral heterogeneity of (18) F-FDG uptake in oral cavity cancer. J Surg Oncol. 2014;110:702–6.
13. Wang D, Koh ES, Descallar J, Pramana A, Vinod SK, Ho Shon I. Application of novel quantitative techniques for fluorodeoxyglucose positron emission tomography/computed tomography in patients with non-small-cell lung cancer. Asia Pac J Clin Oncol. 2016;12:349–58.
14. Hyun SH, Choi JY, Kim K, Kim J, Shim YM, Um SW, et al. Volume-based parameters of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography improve outcome prediction in early-stage non-small cell lung cancer after surgical resection. Ann Surg. 2013;257:364–70.
15. Park SY, Cho A, Yu WS, Lee CY, Lee JG, Kim DJ, et al. Prognostic value of total lesion glycolysis by 18F-FDG PET/CT in surgically resected stage IA non-small cell lung cancer. J Nucl Med. 2015;56:45–9.
16. Melloni G, Gajate AMS, Sestini S, Gallivanone F, Bandiera A, Landoni C, et al. New positron emission tomography derived parameters as predictive factors for recurrence in resected stage I non-small cell lung cancer. Eur J Surg Oncol. 2013;39:1254–61.
17. Ouyang ML, Xia HW, Xu MM, Lin J, Wang LL, Zheng XW, et al. Prediction of occult lymph node metastasis using SUV, volumetric parameters and intratumoral heterogeneity of the primary tumor in T1-2N0M0 lung cancer patients staged by PET/CT. Ann Nucl Med. 2019;33:671–80.
18. Kim SJ, Pak K, Chang S. Determination of regional lymph node status using (18)F-FDG PET/CT parameters in oesophageal cancer patients: Comparison of SUV, volumetric parameters and intratumoral heterogeneity. Br J Radiol. 2016;89:20150673.
19. Kidd EA, Grigsby PW. Intratumoral metabolic heterogeneity of cervical cancer. Clin Cancer Res. 2008;14:5236–41.
20. De Leyn P, Dooms C, Kuzdzal J, Lardinois D, Passlick B, Rami-Porta R, et al. Revised ESTS guidelines for preoperative mediastinal lymph node staging for non-small-cell lung cancer. Eur J Cardiothorac Surg. 2014;45:787–98.
21. Postmus PE, Kerr KM, Oudkerk M, Senan S, Waller DA, Vansteenkiste J, et al. Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28:iv1–21.
22. Detterbeck FC, Boffa DJ, Kim AW, Tanoue LT. The Eighth edition Lung Cancer Stage Classification. Chest. 2017;151:193–203.
23. Kim BS, Pak K, Yi KI, Kim IJ, Roh HJ, Cho KS. Prognostic value of tumoral heterogeneity and volumetric parameters as measured by F18-FDG PET/CT in sinonasal cancer. Eur Arch Otorhinolaryngol. 2017;274:1437–43.
24. Xue X, Zang X, Liu Y, Lin D, Jiang T, Gao J, et al. Independent risk factors for lymph node metastasis in 2623 patients with Non–Small cell lung cancer. Surg Oncol. 2020;34:256–60.
25. Kong M, Jin J, Cai X, Shen J, Ma D, Ye M, et al. Characteristics of lymph node metastasis in resected adenosquamous lung cancer. Medicine (Baltimore). 2017;96:e8870.
26. Wang Y, Jing L, Wang G. Risk factors for lymph node metastasis and surgical methods in patients with early-stage peripheral lung adenocarcinoma presenting as ground glass opacity. J Cardiothorac Surg. 2020;15:121.
27. Miao H, Shaolei L, Nan L, Yumei L, Shanyuan Z, Fangliang L, et al. Occult mediastinal lymph node metastasis in FDG-PET/CT node-negative lung adenocarcinoma patients: Risk factors and histopathological study. Thorac Cancer. 2019;10:1453–60.
28. Kong M, Jin J, Cai X, Shen J, Ma D, Ye M, et al. Characteristics of lymph node metastasis in resected adenosquamous lung cancer. Medicine (Baltimore). 2017;96:e8870.
29. Farsad M. FDG PET/CT in the Staging of Lung Cancer. Curr Radiopharm. 2020;13:195–203.
30. Takehuchi S, Khiewvan B, Fox PS, Swisher SG, Rohren EM, Bassett RL, et al. Impact of initial PET/CT staging in terms of clinical stage, management plan, and prognosis in 592 patients with non-small-cell lung cancer. Eur J Nucl Med Mol Imaging. 2014;41:906–14.
31. Moulla Y, Gradistanac T, Wittekind C, Eichfeld U, Gockel I, Dietrich A. Predictive risk factors for lymph node metastasis in patients with resected non-small cell lung cancer: A case control study. J Cardiothorac Surg. 2019;14:11.
32. Koksal D, Demirag F, Bayiz H, Ozmen O, Tatci E, Berktas B, et al. The correlation of SUVmax with pathological characteristics of primary tumor and the value of Tumor/Lymph node SUVmax ratio for predicting metastasis to lymph nodes in resected NSCLC patients. J Cardiothorac Surg. 2013;8:63.
33. Takahashi Y, Suzuki S, Matsutani N, Kawamura M. 18F-fluorodeoxyglucose positron emission tomography/computed tomography in the evaluation of clinically node-negative non-small cell lung cancer. Thorac Cancer. 2019;10:413–20.
34. Smith DE, Fernandez Aramburu J, Da Lozzo A, Montagne JA, Beveraggi E, Dietrich A. Accuracy of positron emission tomography and computed tomography (PET/CT) in detecting nodal metastasis according to histology of non-small cell lung cancer. Updates Surg. 2019;71:741–6, http://dx.doi.org/10.1007/s13304-019-00680-x.
35. Yilmaz U, Özmen Ö, Demiraǧ F, Cengiz T, Kabalak P, Kizilgöz D, et al. The relationship between quantitative positron emission tomography parameters, the invasive lung adenocarcinoma grading system of International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society, and survival. Eurasian J Pulmonol. 2019;21:107–13.
36. Na F, Wang J, Li C, Deng L, Xue J, Lu Y. Primary tumor standardized uptake value measured on F18-fluorodeoxyglucose positron emission tomography is of prediction value for survival and local control in non-small-cell lung cancer receiving radiotherapy: Meta-analysis. J Thorac Oncol. 2014;9:834–42.
37. Birim Ö, Kappetein AP, Stijnen T, Bogers AJJC. Meta-analysis of positron emission tomographic and computed tomographic imaging in detecting mediastinal lymph node metastases in nonsmall cell lung cancer. Ann Thorac Surg. 2005;79:375–82.
38. Kligerman S, Digumarthy S. Staging of non-small cell lung cancer using integrated PET/CT. AJR Am J Roentgenol. 2009;193:1203–11.

39. Kuzucuoglu M, Gokyer A, Kula O, Yekdes A, Sunal B, Karamustafaoglu Y, et al. Relationship between the Size and Location of the Mass and Hilar and Mediastinal Lymph Node Metastasis in Early and Locally Advanced Non-small Cell Lung Canc. J Coll Physicians Surg Pak. 2020;30: 172–6.

40. Endoh H, Yamamoto R, Ichikawa A, Shiozawa S, Nishizawa N, Satoh Y, et al. Clinicopathologic Significance of False-Positive Lymph Node Status on FDG-PET in Lung Cancer. Clin Lung Cancer. 2021;22:218–24.

41. Hellwig D, Graeter TP, Ukena D, Groeschel A, Sybrecht GW, Schaefers HJ, et al. 18F-FDG PET for mediastinal staging of lung cancer: Which SUV threshold makes sense? J Nucl Med. 2007;48:1761–6.

42. Rogasch JMM, Apostolova I, Steffen IG, Steinkrüger FLGA, Genseke P, Riedel S, et al. Standardized visual reading of F18-FDG-PET in patients with non-small cell lung cancer scheduled for preoperative thoracic lymph node staging. Eur J Radiol. 2016;85:1345–50.

43. Rogasch JMM, Frost N, Bluemel S, Michaels L, Penzkofer T, von Laffert M, et al. FDG-PET/CT for pretherapeutic lymph node staging in non-small cell lung cancer: A tailored approach to the ESTS/ESMO guideline workflow. Lung Cancer. 2021;157:66–74.

44. Kim Yil, Kim YJ, Paeng JC, Cheon GJ, Lee DS, Chung JK, et al. Prediction of breast cancer recurrence using lymph node metabolic and volumetric parameters from 18F-FDG PET/CT in operable triple-negative breast cancer. Eur J Nucl Med Mol Imaging. 2017;44:1787–95.

45. Nakanishi K, Nakamura S, Sugiyama T, Kadomatsu Y, Ueno H, Goto M, et al. Diagnostic utility of metabolic parameters on FDG PET/CT for lymph node metastasis in patients with cN2 non-small cell lung cancer. BMC Cancer. 2021;21:983.

46. Hua J, Li L, Liu L, Liu Q, Liu Y, Chen X. The diagnostic value of metabolic, morphological and heterogeneous parameters of 18F-FDG PET/CT in mediastinal lymph node metastasis of non-small cell lung cancer. Nucl Med Commun. 2021;42:1247–53.